GlassScriptPhysician profile
Richard E Burgess
NPI 1649340530
$3,875.40
in general payments reported to CMS, 2019-2025
27 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $34.59 · 2021: $714 · 2022: $582 · 2023: $135 · 2024: $181 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insightec,INC | $1,356.66 | 2019 | |
| Stryker Corporation | $838.78 | 2021-2025 | Trevo, Surpass Evolve |
| Medtronic USA, INC. | $329.55 | 2019 | |
| Microvention, INC. | $284.86 | 2019-2023 | Eric Retrieval Device |
| Medtronic, INC. | $235.51 | 2021-2022 | |
| Depuy Synthes Sales INC. | $125.10 | 2025 | Embotrap |
| Chiesi USA, INC. | $120.03 | 2021 | |
| Medical Device Business Services, INC. | $93.85 | 2019 | |
| Sk Life Science, INC. | $62.94 | 2022-2024 | |
| Tg Therapeutics, INC. | $48.83 | 2025 | |
| Pfizer INC. | $42.30 | 2023-2024 | |
| Emd Serono, INC. | $40.64 | 2022-2024 | |
| Kyowa Kirin, INC. | $39.92 | 2019-2023 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $38.87 | 2020-2022 | |
| Penumbra, INC. | $27.43 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.54 | 2025 | |
| Jazz Pharmaceuticals INC. | $19.18 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.80 | 2022 | |
| Argenx US, INC. | $16.67 | 2023 | Vyvgart |
| Merz Pharmaceuticals, LLC | $15.74 | 2025 | Xeomin |
| Biocodex, INC. | $15.63 | 2025 | |
| Biogen, INC. | $15.28 | 2023 | Spinraza |
| Acadia Pharmaceuticals INC | $14.66 | 2019 | |
| Lilly USA, LLC | $14.58 | 2023 | Emgality, Reyvow |
| Celgene Corporation | $14.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.27 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Burgess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.